[
  {
    "ts": null,
    "headline": "Battle of Benefits: Will UNH Deliver the Bigger Dose or CVS? (Revised)",
    "summary": "CVS's rising margins, stronger guidance and sharper valuation edge make it stand out in the UNH vs. CVS upside debate.",
    "url": "https://finnhub.io/api/news?id=25cb3c8a6f2365bfe6112a3000a06e716dcc999fc6096a0a46354b65484fd774",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764183900,
      "headline": "Battle of Benefits: Will UNH Deliver the Bigger Dose or CVS? (Revised)",
      "id": 137619109,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "UNH",
      "source": "Yahoo",
      "summary": "CVS's rising margins, stronger guidance and sharper valuation edge make it stand out in the UNH vs. CVS upside debate.",
      "url": "https://finnhub.io/api/news?id=25cb3c8a6f2365bfe6112a3000a06e716dcc999fc6096a0a46354b65484fd774"
    }
  },
  {
    "ts": null,
    "headline": "CURE: Analysts Strike A Cautious Tone Heading Into 2026",
    "summary": "Discover why the Direxion Healthcare Bull 3X ETF is outperforming in 2025. Learn about key risks, returns, and buy ratings.",
    "url": "https://finnhub.io/api/news?id=a5ef5754831c30f25c83c66be5e038c5194b41554790fb800b0ad9b7a81a6a4b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764174517,
      "headline": "CURE: Analysts Strike A Cautious Tone Heading Into 2026",
      "id": 137615429,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2009808479/image_2009808479.jpg?io=getty-c-w1536",
      "related": "UNH",
      "source": "SeekingAlpha",
      "summary": "Discover why the Direxion Healthcare Bull 3X ETF is outperforming in 2025. Learn about key risks, returns, and buy ratings.",
      "url": "https://finnhub.io/api/news?id=a5ef5754831c30f25c83c66be5e038c5194b41554790fb800b0ad9b7a81a6a4b"
    }
  },
  {
    "ts": null,
    "headline": "Battle of Benefits: Will UNH Deliver the Bigger Dose or CVH?",
    "summary": "CVS's rising margins, stronger guidance and sharper valuation edge make it stand out in the UNH vs. CVS upside debate.",
    "url": "https://finnhub.io/api/news?id=3cdf218e1f2f7badaf1fd331e991eeda181a4cde066e5cd9b561395572f837f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764172680,
      "headline": "Battle of Benefits: Will UNH Deliver the Bigger Dose or CVH?",
      "id": 137614515,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "UNH",
      "source": "Yahoo",
      "summary": "CVS's rising margins, stronger guidance and sharper valuation edge make it stand out in the UNH vs. CVS upside debate.",
      "url": "https://finnhub.io/api/news?id=3cdf218e1f2f7badaf1fd331e991eeda181a4cde066e5cd9b561395572f837f1"
    }
  },
  {
    "ts": null,
    "headline": "Contrarian Plays And Real Asset Opportunities From Next Gen Investors",
    "summary": "Rob Isbitts checks in with analysts Julia Ostian, Kenio Fontes, and Jack Bowman to see how they're thinking about the current market.",
    "url": "https://finnhub.io/api/news?id=74010ccfce072633425bbf78e17a6ca5cc22bb216835aba0a2d9c0f73a698212",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764166800,
      "headline": "Contrarian Plays And Real Asset Opportunities From Next Gen Investors",
      "id": 137615029,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1425061324/image_1425061324.jpg?io=getty-c-w1536",
      "related": "UNH",
      "source": "SeekingAlpha",
      "summary": "Rob Isbitts checks in with analysts Julia Ostian, Kenio Fontes, and Jack Bowman to see how they're thinking about the current market.",
      "url": "https://finnhub.io/api/news?id=74010ccfce072633425bbf78e17a6ca5cc22bb216835aba0a2d9c0f73a698212"
    }
  }
]